Natasha Giordano - 11 Dec 2025 Form 4 Insider Report for ORAGENICS INC (OGEN)

Role: Director
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Natasha Giordano
Issuer symbol: OGEN
Transactions as of: 11 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 15 Dec 2025, 16:49:15 UTC
Previous filing: 02 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Giordano Natasha	Director	1990 MAIN STREET, SUITE 750, SARASOTA	/s/ Julio C. Esquivel as Attorney-In-Fact for Natasha Giordano	15 Dec 2025	0001315585

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OGEN	Non-Employee Director Option (Right to Buy)	Award	$0	+38,320		$0.000000	38,320	11 Dec 2025	Common Stock	38,320	$1.03	Direct	F1
transaction	OGEN	Non-Employee Director Option (Right to Buy)	Award	$0	+125,000		$0.000000	125,000	11 Dec 2025	Common Stock	125,000	$0.9300	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an initial equity award upon appointment to the Company's board of directors (the "Board") of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan that vests immediately. The option exercise price is the Company's closing price on the date immediately prior to the reporting person's appointment to the Company's Board. The Board granted the options on December 11, 2025.
F2	Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.

Content

Represents an initial equity award upon appointment to the Company's board of directors (the "Board") of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan that vests immediately. The option exercise price is the Company's closing price on the date immediately prior to the reporting person's appointment to the Company's Board. The Board granted the options on December 11, 2025.

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.